BIO-TECHNE AND ALZpath ANNOUNCE STRATEGIC PARTNERSHIP TO ADVANCE NEURODEGENERATIVE DISEASE RESEARCH
Bio-Techne (NASDAQ: TECH) has announced a strategic partnership with ALZpath to advance neurodegenerative disease research, particularly Alzheimer's. The collaboration combines Bio-Techne's Ella™ automated immunoassay platform with ALZpath's proprietary pTau217 antibody to create the Simple Plex Human Phospho-Tau (T217) ALZpath Assay.
The new assay enables detection of pTau217, a biomarker associated with Alzheimer's disease, in plasma samples within 90 minutes without manual intervention. This integration aims to increase efficiency, scalability, and precision in neurodegenerative disease research while accelerating clinical decisions.
Bio-Techne (NASDAQ: TECH) ha annunciato una partnership strategica con ALZpath per avanzare nella ricerca sulle malattie neurodegenerative, in particolare l'Alzheimer. La collaborazione combina la piattaforma Ella™ di immunoassay automatizzato di Bio-Techne con l'anticorpo pTau217 brevettato di ALZpath per creare il test Simple Plex Human Phospho-Tau (T217) ALZpath.
Il nuovo test consente la rilevazione di pTau217, un biomarcatore associato alla malattia di Alzheimer, in campioni di plasma in 90 minuti senza intervento manuale. Questa integrazione mira ad aumentare efficienza, scalabilità e precisione nella ricerca sulle malattie neurodegenerative, accelerando al contempo le decisioni cliniche.
Bio-Techne (NASDAQ: TECH) ha anunciado una asociación estratégica con ALZpath para avanzar en la investigación de enfermedades neurodegenerativas, particularmente el Alzheimer. La colaboración combina la plataforma Ella™ de inmunoensayo automatizado de Bio-Techne con el anticuerpo pTau217 patentado de ALZpath para crear el ensayo Simple Plex Human Phospho-Tau (T217) ALZpath.
El nuevo ensayo permite la detección de pTau217, un biomarcador asociado con la enfermedad de Alzheimer, en muestras de plasma en 90 minutos sin intervención manual. Esta integración tiene como objetivo aumentar la eficiencia, escalabilidad y precisión en la investigación de enfermedades neurodegenerativas, al mismo tiempo que acelera las decisiones clínicas.
Bio-Techne (NASDAQ: TECH)는 ALZpath와 전략적 파트너십을 맺고 신경퇴행성 질병 연구, 특히 알츠하이머 연구를 진행한다고 발표했습니다. 이번 협력은 Bio-Techne의 자동화된 면역 분석 플랫폼인 Ella™와 ALZpath의 특허받은 pTau217 항체를 결합하여 Simple Plex Human Phospho-Tau (T217) ALZpath 분석을 생성합니다.
새로운 분석을 통해 알츠하이머 질병과 관련된 바이오마커인 pTau217를 90분 내에 수동 개입 없이 혈장 샘플에서 검출할 수 있습니다. 이러한 통합은 신경퇴행성 질병 연구의 효율성, 확장성 및 정확성을 높이고 임상 결정을 가속화하는 것을 목표로 하고 있습니다.
Bio-Techne (NASDAQ: TECH) a annoncé un partenariat stratégique avec ALZpath pour faire avancer la recherche sur les maladies neurodégénératives, en particulier la maladie d'Alzheimer. La collaboration combine la plateforme d'immunoessai automatisé Ella™ de Bio-Techne avec l'anticorps pTau217 breveté d'ALZpath pour créer le test Simple Plex Human Phospho-Tau (T217) ALZpath.
Le nouveau test permet de détecter le pTau217, un biomarqueur associé à la maladie d'Alzheimer, dans des échantillons de plasma en 90 minutes sans intervention manuelle. Cette intégration vise à accroître l'efficacité, l'évolutivité et la précision dans la recherche sur les maladies neurodégénératives tout en accélérant les décisions cliniques.
Bio-Techne (NASDAQ: TECH) hat eine strategische Partnerschaft mit ALZpath angekündigt, um die Forschung zu neurodegenerativen Erkrankungen, insbesondere Alzheimer, voranzutreiben. Die Zusammenarbeit kombiniert die automatisierte Immunassay-Plattform Ella™ von Bio-Techne mit dem eigenen pTau217-Antikörper von ALZpath, um den Simple Plex Human Phospho-Tau (T217) ALZpath-Test zu entwickeln.
Der neue Test ermöglicht die Detektion von pTau217, einem Biomarker, der mit der Alzheimer-Krankheit assoziiert ist, in Plasmaproben innerhalb von 90 Minuten ohne manuelle Eingriffe. Diese Integration zielt darauf ab, die Effizienz, Skalierbarkeit und Präzision in der Forschung zu neurodegenerativen Erkrankungen zu erhöhen und gleichzeitig klinische Entscheidungen zu beschleunigen.
- Partnership enables faster detection of Alzheimer's biomarkers (90-minute processing)
- Technology allows for less invasive sample collection methods
- Automated process increases efficiency and precision in research
- Integration creates new opportunities in treatment development and validation
- None.
Insights
The partnership between Bio-Techne and ALZpath represents a significant advancement in Alzheimer's disease research capabilities. The integration of ALZpath's pTau217 antibody with Bio-Techne's Ella platform creates a powerful diagnostic tool that offers several key advantages:
- 90-minute automated processing time
- Use of less invasive plasma samples
- Increased precision and scalability
This strategic partnership positions Bio-Techne to capture a larger share of the expanding Alzheimer's diagnostic market. The collaboration addresses critical market needs for faster, more accurate and less invasive testing methods. With over 55 million people worldwide affected by dementia and numbers expected to triple by 2050, demand for such diagnostic tools will likely surge. The automated nature of the Ella platform could drive adoption in research laboratories and clinical settings, potentially generating recurring revenue through reagent sales and platform placements. This move aligns with the industry trend toward automated, high-throughput diagnostic solutions and could strengthen Bio-Techne's competitive position against other players in the neurodegenerative disease space.
The ALZpath pTau217 (phosphorylated Tau217) antibody is the leading antibody used to detect the pTau217 biomarker. Increased levels of pTau217 are associated with amyloid plaques and tau tangles, the hallmark features of Alzheimer's disease.
Running the Simple Plex Human Phospho Tau 217 ALZpath Assay on the Ella system will enable researchers to detect the pTau217 signal in less invasive sample collection types, like plasma samples, in just 90 minutes with no manual intervention, increasing efficiency, scalability, and precision while providing the necessary data to help accelerate clinical decisions.
"Our partnership with ALZpath represents a major step forward in our commitment to advancing neurodegenerative disease research," said Will Geist, President of Bio-Techne's Protein Sciences Segment. "We're excited to see the impact that this easy-to-use, hands-free platform will have on advancing research in this critical field."
"As cases of Alzheimer's disease continue to rise around the world, this collaboration provides an opportunity to leverage our proprietary pTau217 antibody to advance promising research and development of new treatments," said Chad Holland, CEO at ALZpath. "The integration of our pTau217 antibody into Bio-Techne's advanced immunoassay technology creates a unique toolset that will empower researchers around the world to explore new methods of treatment and validate benefits that may result from those interventions, pushing the industry forward."
About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated approximately
Contact: David Clair, Vice President, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416
About ALZpath
ALZpath is a leading developer of innovative diagnostic tools and solutions for Alzheimer's disease and related dementias. The novel ALZpath pTau217 antibody, integral to the most advanced, widely available blood-based tests to detect Alzheimer's disease, is transforming diagnosis and treatment monitoring, providing accurate and accessible tools for researchers and healthcare professionals worldwide. To help millions of patients in need, ALZpath democratizes access to its proprietary robust antibody, which is used by researchers, clinicians, and industry partners around the world to accelerate the discovery of new treatments and improve patient care.
To learn more about the company, please visit https://alzpath.bio/ and follow us on LinkedIn.
Contact:
Nechama Rosengarten
nechama.rosengarten@finnpartners.com
551-444-0784
View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-and-alzpath-announce-strategic-partnership-to-advance-neurodegenerative-disease-research-302307463.html
SOURCE Bio-Techne Corporation
FAQ
What is the purpose of Bio-Techne's partnership with ALZpath announced in 2024?
How long does the new TECH Simple Plex Human Phospho-Tau Assay take to process samples?
What type of samples can be used with Bio-Techne's new Alzheimer's detection assay?
What biomarker does the new TECH and ALZpath assay detect?
